Autolus: MAK Group Reports 12.6% Stake
Autolus Therapeutics plc ownership update: MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman report beneficial ownership of 33,621,487 ADS (each ADS represents one ordinary share), equal to 12.6% of the outstanding ordinary shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Autolus Therapeutics plc ownership update: MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman report beneficial ownership of 33,621,487 ADS (each ADS represents one ordinary share), equal to 12.6% of the outstanding ordinary shares. The percent calculation is based on 266,155,786 ordinary shares outstanding as of May 13, 2026, as reported in the issuer's Form 10-Q. The filing shows shared voting and dispositive power over the 33,621,487 ADS and is signed by Michael A. Kaufman.
Insights
MAK group discloses a 12.6% beneficial stake in Autolus.
The filing reports 33,621,487 ADS held with shared voting and dispositive power, calculated against May 13, 2026 outstanding shares of 266,155,786. This disclosure clarifies ownership and control structure for regulatory and market transparency.
Timing and cash‑flow treatment are not stated in the excerpt; subsequent filings would show any transactional activity. Market impact depends on whether the holders trade or engage with the company.
Key Figures
Key Terms
ADS financial
Beneficial ownership regulatory
Schedule 13G/A regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does MAK Capital hold in Autolus (AUTL)?
How is an ADS defined in this filing for AUTL?
Who signed the Schedule 13G/A for this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.